Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Ronglih Liao, PhD
Researcher Co-Director
Stanford Amyloid Center
Stanford University School of Medicine
1651 Page Mill Road, Room 2346
Stanford, California, United States
Ronglih Liao is Co-Director of the Stanford Amyloid Center and Professor of Medicine at Stanford University School of Medicine. She is also a visiting Professor of Medicine at Brigham and Women’s Hospital, Harvard Medical School. The major goal of her research program focuses on understanding the mechanisms that underlie the pathophysiology of heart failure and developing novel treatments to combat this process. Her laboratory has played an international leading role in the study of amyloid light chain (AL) cardiomyopathy, a rare and fatal form of cardiovascular disease.
She was the first female Council Chair (2016-2018) of AHA Basic Cardiovascular Science Council. Dr. Liao has served numerous major leadership roles, with service to national and international societies, committees, and funding agencies and as a committee member or reviewer.
Moreover, Dr. Liao has continued her competitive independent investigation, under direct research funding from the NIH continuously for over a decade. Over the years, Liao Lab has made critical contributions to the understanding of the molecule mechanisms that underlie the development of amyloid cardiomyopathy as well as the regulation of both cell fate and function in adult cardiac progenitor cells.
Representative Publications:
myBinderRelated Content
-
Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CMThe 30-month results of the phase 3 ATTR...
-
Frederick L. Ruberg, MDFrederick L. Ruberg, MD is an Associate ...
-
Libin Wang, MD, PhDDr. Libin Wang is an Assistant Professor...
-
Farooq H. Sheikh, MDFarooq Sheikh is an attending physician ...
-
Julie L. Rosenthal, MDJulie L. Rosenthal is a Cardiologist-Int...
-
ESC: Tafamidis Cuts Deaths, Admissions in TTR Cardiac AmyloidosisTreatment with the investigational drug ...
-
Features of Atrial Fibrillation in Wild-Type Transthyretin Cardiac Amyloidosis: A Systematic Review and Clinical Exp...Aims: Wild-type transthyretin (ATTRwt) ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
